Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21779826 | 0.82 | ENPP3 (0.32) | ENPP3ENPP1 | |
| SCHEMBL25106939 | 0.79 | ENPP3 (0.31) | ENPP3ENPP1 | |
| SCHEMBL19011964 | 0.77 | DHFR (0.30) | — | |
| SCHEMBL20096318 | 0.74 | ENPP3 (0.34) | ENPP3ENPP1 | |
| SCHEMBL24974327 | 0.73 | NR1I2 (0.33) | — | |
| SCHEMBL22276368 | 0.72 | — | — | |
| SCHEMBL17000221 | 0.71 | ENPP3 (0.35) | ENPP3ENPP1 | |
| SCHEMBL10771087 | 0.71 | — | — | |
| SCHEMBL18214836 | 0.71 | LMNA (0.33) | ENPP3ENPP1 | |
| SCHEMBL23791344 | 0.69 | CA12 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | ENPP3 690/4885ENPP1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.